Fintel reports that on December 19, 2025, JP Morgan initiated coverage of Oculis Holding (NasdaqGM:OCS) with a Overweight recommendation.
Analyst Price Forecast Suggests 111.83% Upside
As of December 5, 2025, the average one-year price target for Oculis Holding is $44.99/share. The forecasts range from a low of $29.29 to a high of $57.75. The average price target represents an increase of 111.83% from its latest reported closing price of $21.24 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Oculis Holding is 5MM, an increase of 553.98%. The projected annual non-GAAP EPS is -2.02.
What is the Fund Sentiment?
There are 34 funds or institutions reporting positions in Oculis Holding. This is an decrease of 2 owner(s) or 5.56% in the last quarter. Average portfolio weight of all funds dedicated to OCS is 1.84%, an increase of 1.63%. Total shares owned by institutions increased in the last three months by 91.27% to 12,228K shares.
What are Other Shareholders Doing?
EQT Fund Management S.a r.l. holds 5,900K shares representing 10.21% ownership of the company.
Pivotal bioVenture Partners Investment Advisor holds 2,301K shares representing 3.98% ownership of the company. No change in the last quarter.
Standard Life Aberdeen holds 1,253K shares representing 2.17% ownership of the company. No change in the last quarter.
Nan Fung Group Holdings holds 515K shares representing 0.89% ownership of the company. No change in the last quarter.
Tekla Healthcare Opportunities Fund holds 426K shares representing 0.74% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
